Table 1.
Demographic and clinical characteristics and treatment modalities in patients with Brucella arhtritis
| Clinical features | Mean ± SD, median range or number (%) (n:64) |
|---|---|
| Mean age (month) | 92.3 ± 41.2 |
| Gender | |
| Male | 34 (53.1) |
| Female | 30 (46.9) |
| Duration of hospitalization (day) | 6 (2–76) |
| Symptoms and clinical findings | |
| Arthralgia | 64 (100) |
| Joint pain | 61 (95.3) |
| Fever | 55 (85.9) |
| Myalgia | 49 (76.6) |
| Anorexia | 46 (71.9) |
| Weakness | 40 (62.5) |
| Shivering | 39 (60.9) |
| Restriction of movement | 36 (56.2) |
| Diaphoresis | 33 (51.6) |
| Swelling | 22 (34.3) |
| Increase temperature on joint | 22 (34.3) |
| Joint redness | 22 (34.3) |
| Headache | 20 (31.3) |
| Abdominal pain | 14 (21.9) |
| Joint effusion | 13 (20.3) |
| Chest pain | 11 (17.2) |
| Neck pain | 2 (3.1) |
| Joint involvement | |
| Ankle | 34 (53.1) |
| Knee | 30 (46.9) |
| Laboratory findings | |
| Erythrocyte sedimentation rate (mm/h) | 40.9 ± 20.4 |
| C-reactive protein (mg/L) | 28.1 ± 22.4 |
| Brucella hemagglutination test | |
| 160 | 10 (15.8) |
| 320 | 25 (39.1) |
| ≥640 | 29 (45.3) |
| Positive culture | |
| Blood | 4 (6.3) |
| Joint puncture | 4 (6.3) |
| Blood + Joint puncture | 5 (7.9) |
| Treatment | |
| Rifampicin + Tetracycline + Streptomycin | 13 (20.3) |
| Rifampicin + Tetracycline + Gentamicin | 14 (21.8) |
| Rifampicin + TMP-SMX + Gentamicin | 37 (57.8) |
TMP-SMX trimethoprim-sulfamethoxazole, SD standard deviation